A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis
Inflammatory Intestinal Diseases · 2020 · 5 (4) · 180-190
DOI: 10.1159/000509393 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 21.08.2020. Verfasst von Heinfried H Radeke und 10 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, Germany. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims: KRP203 is a potent oral agonist of the sphingosine-1-phosphate receptor subtype 1 that induces the sequestration of peripheral lymphocytes, thereby potentially reducing the number of activated lymphocytes circulating to the gastrointestinal tract.
Methods
We conducted a multicentre, double-blind, placebo-controlled, parallel-group, proof-of-concept study to evaluate the efficacy, safety, and tolerability of KRP203 in patients with moderately active 5-aminosalicylate-refractory ulcerative colitis (UC). Patients were randomly assigned to receive 1.2 mg KRP203 or placebo daily for 8 weeks. Primary efficacy variable was clinical remission, defined as partial Mayo Score 0–1 and modified Baron Score 0–1 with rectal bleeding subscore 0.
Results
KRP203 was safe and well tolerated overall. The most common adverse events (AEs) were gastrointestinal disorders and headache. Importantly, no KRP203-related cardiac AEs were reported. Total peripheral lymphocytes and selectively affected lymphocyte subtypes decreased, causing marked decreases in naive and central memory CD4+ and CD8+ T cells, and also in B cells. Clinical remission occurred in 2/14 (14%) patients under KRP203, compared with 0/8 (0%) under placebo.
Conclusions
Overall, KRP203 was safe and well tolerated by patients with UC. Importantly, no cardiac AEs were reported. Although KRP203 did not meet the minimum clinically relevant threshold for efficacy, the results may suggest that KRP203 treatment is superior to placebo. However, in this small study population, the difference was insignificant. Based on these data, studies with an improved design and a larger population should be considered.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt am Main, Germany.
- Hospital of the Goethe University Frankfurt/Main, Frankfurt am Main, Germany.
- Translational Research in Gastrointestinal Disorders, School of Medicine, University of Leuven, Leuven, Belgium.
- Clinic of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
- IBD Centre, Department of Medicine, McGill University, Montreal, Québec, Canada.
- Novartis Basel, Basel, Switzerland.
Zitieren
APA
Radeke, H. H., Stein, J., Van Assche, G., Rogler, G., Lakatos, P. L., Muellershausen, F., Moulin, P., Jarvis, P., Colin, L., Gergely, P., & Kruis, W. (2020). A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflammatory Intestinal Diseases, 5(4), 180-190. https://doi.org/10.1159/000509393
Vancouver
Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, et al. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflammatory Intestinal Diseases. 2020;5(4):180-190. doi:10.1159/000509393
BibTeX
@article{Radeke2020,
author = {Radeke, Heinfried H and Stein, Jürgen and Van Assche, Gert and Rogler, Gerhard and Lakatos, Peter L and Muellershausen, Florian and Moulin, Pierre and Jarvis, Philip and Colin, Laurence and Gergely, Peter and Kruis, Wolfgang},
title = {A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis},
journal = {Inflammatory Intestinal Diseases},
year = {2020},
volume = {5},
number = {4},
pages = {180--190},
doi = {10.1159/000509393}
}
EUVIMED